Depressive symptomatology in men receiving androgen deprivation therapy for prostate cancer: a controlled comparison.
Depressive symptomatology in men receiving androgen deprivation therapy for prostate cancer: a controlled comparison.
复制标题
DOI：
10.1002/pon.3608
复制
发表时间：
2015-04
期刊：
影响因子：
3.6
通讯作者：
Jacobsen, Paul B.
中科院分区：
文献类型：
--
作者：
Lee, Morgan;Jim, Heather S.;Fishman, Mayer;Zachariah, Babu;Heysek, Randy;Biagioli, Matthew;Jacobsen, Paul B.
接受雄激素剥夺疗法（ADT）的前列腺癌患者经常会经历许多身体和心理副作用。 ADT 可能与抑郁症风险增加有关，但 ADT 与抑郁症之间的关系尚不完全清楚。本研究采用纵向设计来评估接受 ADT 的患者与两组匹配对照患者的抑郁症状。参与者是开始 ADT 治疗的男性（ADT+ 组；n = 61）及其匹配的对照：接受根治性前列腺切除术治疗的前列腺癌患者（ADT− 组；n = 61）和非癌症对照（CA− 组；n = 61）。在 ADT 开始时和六个月后使用流行病学研究中心抑郁量表评估抑郁症状。对每个时间点的组间以及随时间推移的组内抑郁症状和有临床意义的抑郁症状发生率的差异进行分析。结果：在基线和随访期间，ADT+ 参与者表现出抑郁症状增加，并且具有临床意义的抑郁症状发生率增加 (ps < .05)。 ADT+ 参与者在随访中还报告了比两个对照组更严重的抑郁症状 (ps < .001)。在两个时间点，ADT+ 组出现临床显着抑郁症状的比例均高于 ADT- 和 CA- 组（基线：28%、5%、12%；随访：39%、9%、11%）。研究结果支持 ADT 治疗会增加抑郁症的假设，并表明应探索 ADT 与抑郁症相关的机制，并且接受 ADT 治疗的前列腺癌患者应特别关注抑郁症筛查和干预。
Prostate cancer patients who receive androgen deprivation therapy (ADT) often experience many physical and psychological side effects. ADT may be associated with increased risk for depression, but the relationship between ADT and depression is not fully understood. This study used a longitudinal design to assess depressive symptomatology in patients receiving ADT compared to two groups of matched controls. Participants were men initiating ADT treatment (ADT+ group; n = 61) and their matched controls: prostate cancer patients treated with radical prostatectomy (ADT− group; n = 61) and no-cancer controls (CA− group; n = 61). Depressive symptomatology was assessed using the Center for Epidemiological Studies Depression Scale at ADT initiation and again six months later. Differences in depressive symptomatology and rates of clinically-significant depressive symptomatology were analyzed between groups at each time point and within groups over time. Results: Between baseline and follow-up, ADT+ participants demonstrated increased depressive symptomatology and increased rates of clinically-significant depressive symptomatology (ps < .05). ADT+ participants also reported greater depressive symptomatology than both control groups at follow-up (ps < .001). Rates of clinically-significant depressive symptomatology were higher in the ADT+ group than the ADT− and CA− groups at both time points (baseline: 28%, 5%, 12%; follow-up: 39%, 9%, 11%). Findings support the hypothesis that ADT administration yields increases in depression and suggest that the mechanism behind ADT’s association with depression should be explored and that prostate cancer patients treated with ADT should receive particular focus in depression screening and intervention.
登录
查看更多内容
影响因子：
6.2
作者：
Shahinian, VB;Kuo, YF;Goodwin, JS
通讯作者：
Goodwin, JS
影响因子：
4.7
作者：
Chen, Allen C;Petrylak, Daniel P
通讯作者：
Petrylak, Daniel P
影响因子：
4.7
作者：
Hann, D;Winter, K;Jacobsen, P
通讯作者：
Jacobsen, P
影响因子：
8.4
作者：
Stone, P;Hardy, J;Richards, M
通讯作者：
Richards, M
影响因子：
3.6
作者：
Pirl, WF;Siegel, GI;Smith, MR
通讯作者：
Smith, MR